Roche’s Virtual Neurology/ACTRIMS Investor Event
Roche has hosted a virtual event on Monday, 9 February 2026
| Agenda | |
|---|---|
| Introduction | Bruno Eschli, Head of Investor Relations |
| MS franchise/pipeline update | Hideki Garren, SVP, Global Head of Product Development Neurology |
| Ph III (FENtrepid) fenebrutinib vs. Ocrevus in PPMS | Amit Bar-Or, MD, FRCPC, Director, Center for Neuroinflammation and Experimental Therapeutics and Chief, Multiple Sclerosis Division, Department of Neurology Perelman Center for Advanced Medicine (PCAM), University of Pennsylvania |
| Q&A |
Webinar Replay
Please click the video below to watch the replay of the webinar.
Investors